ERBB2 and gallbladder cancer: The use of trastuzumab, an antibody targeting HER2, in combination with chemotherapy showed a promising response in gallbladder cancer with HER2/neu genetic aberrations or protein overexpression, but no therapeutic effects on CCA in a small retrospective cohort [36].